Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

The Effect of Hyperthermic Intravesical Perfusion on the Risk of Intraoperative Implantation of Muscle-invasive Bladder Urothelial Carcinoma and Its Safety Analysis

To evaluate the effect of hyperthermic intravesical perfusion on the risk of intraoperative implantation of muscle-invasive bladder urothelial carcinoma and its safety.

Study Overview

• Status: Recruiting
• Conditions: Intraoperative Complications; Perfusion; Complications; High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma
• Intervention / Treatment: Device: hyperthermic intravesical perfusion

Detailed Description

The participants will be divided into two groups (the experimental group and control group). Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy. Participants in the control group will receive radical cystectomy alone.

After follow-up, the effect of hyperthermic intravesical perfusion on the risk of intraoperative implantation of muscle-invasive bladder urothelial carcinoma and its safety will be evaluated.

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Huaqi Yin; Phone Number: +8613366621170; Email: yhq901212@163.com

Study Locations

• China
  • Henan
    • Zhengzhou, Henan, China, 450008
      • Recruiting
      • BR-PRG
      • Contact: Huaqi Yin, MD.; Phone Number: +8613366621170; Email: yhq901212@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Be willing and able to provide written informed consent for the trial.
• 18-75 years of age on day of signing informed consent.
• Have histologically confirmed muscle invasive disease of the urinary bladder.
• Histology must be urothelial carcinoma (transitional cell carcinoma) or urothelial carcinoma with mixed histology/features.
• Clinical stage II-III and Have a surgical evaluation that documents the plan for multimodality therapy with a consolidative radical cystectomy.
• Eastern Cooperative Oncology Group 0-1 and good organ function.

Exclusion Criteria:

• A non-surgical approach recommended by the treating urologist due to any reason.
• Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 28 days prior to study registration.
• Has a diagnosis of immunodeficiency or received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registration.
• Has a known additional malignancy that is progressing or required treatment ≤ 48 months of study registration. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer.
• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• Has an active autoimmune disease requiring systemic treatment.
• Has known evidence of interstitial lung disease or active, non-infectious pneumonitis.
• Has an active infection requiring systemic therapy.
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
• Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
• Has received prior therapy with an anti-programmed cell death 1, anti-programmed cell death-Ligand 1 antibody.
• Has a known history of Human Immunodeficiency Virus.
• Has known active Hepatitis B or Hepatitis C.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: The experimental group; Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy.	Device: hyperthermic intravesical perfusion; Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy
No Intervention: The control group; Participants in the control group will receive radical cystectomy alone.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of intraoperative tumor cell dissemination	The rate of intraoperative tumor cell dissemination will be evaluated by lavage cytology of operating field	3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to disease progression	Disease progression was defined as recurrence or metastasis	3 years

Collaborators and Investigators

• Sponsor: Henan Cancer Hospital

Study record dates

Study Major Dates

• Study Start (Actual): June 6, 2022
• Primary Completion (Anticipated): December 1, 2024
• Study Completion (Anticipated): December 1, 2025

Study Registration Dates

• First Submitted: November 24, 2021
• First Submitted That Met QC Criteria: March 2, 2022
• First Posted (Actual): March 11, 2022

Study Record Updates

• Last Update Posted (Actual): September 16, 2022
• Last Update Submitted That Met QC Criteria: September 15, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Carcinoma; Carcinoma, Transitional Cell; Intraoperative Complications
• Other Study ID Numbers: Ytj20210926

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No